Epic-Based Clinician Notification for Type 2 Diabetes with Albuminuria
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes and confirmed albuminuria.
The main question it aims to answer is:
• Does an Epic clinician notification improve initiation of guideline-directed CKM therapies compared with usual care?
Researchers will compare an Epic in-basket clinician notification strategy with usual care.
In the intervention arm, the treating clinician will receive an Epic notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing electronic health record (EHR) data. Participants in the usual care arm will receive standard clinical care without notification.
Who Is on the Research Team?
Shahzeb Khan, MD
Principal Investigator
Baylor Scott and White Health
Are You a Good Fit for This Trial?
This trial is for adults with type 2 diabetes and confirmed albuminuria (protein in the urine), which means they have signs of kidney problems related to diabetes.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Randomization and Intervention
Participants are randomized to either the Epic clinician notification strategy or usual care. In the intervention arm, clinicians receive notifications about potential eligibility for CKM therapies.
Follow-up
Participants are monitored for initiation of guideline-directed CKM therapies and clinician responses to notifications.
What Are the Treatments Tested in This Trial?
Trial Overview
The study compares two approaches: one group has their doctors receive electronic notifications about patients' kidney issues to encourage starting recommended treatments, while the other group receives usual care without these alerts. Participants are randomly assigned to each group.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Treating clinicians receive an Epic in-basket notification identifying confirmed albuminuria and potential eligibility for guideline-directed CKM therapies using existing EHR data. All treatment decisions remain at the discretion of the treating clinician.
Participants receive standard clinical care without Epic clinician notification. Treatment decisions, including initiation of guideline-directed CKM therapies, remain at the discretion of the treating clinician.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baylor Research Institute
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.